HCPLive Podcasts

Ahead of the American College of Rheumatology 2022 Convergence meeting on Nov. 10-14, our editorial team sat down with planning committee member Zsuzsanna McMahan, MD, MHS, of Johns Hopkins University School of Medicine, to take a deep dive into the upcoming meeting.

The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.

One of the most notable topics discussed at the 2022 American Academy of Ophthalmology Meeting in Chicago was new advancements in geographic atrophy (GA) treatment. A form of advanced age-related macular degeneration (AMD), there are no currently available treatments for the debilitating disease. In this episode of DocTalk , we spoke with Arshad Khanani, MD, Director of Clinical Research, Sierra E...

In the wake of Newborn Screening Awareness Month, this episode dives into a novel diagnostic precision medicine guidance tool called BeginNGS. Catherine Nester, RN, and Dr. Stephen Kingsmore, discuss the pivotal role of newborn screening in diagnosing rare diseases.  As representatives from collaborating partners Inozyme Pharma and Rady Children's Institute that created this tool, they explain the...

Martha Gulati, MD, Director of Preventive Cardiology, Associate Director of the Barbara Streisand Women’s Heart Center, Associate Director of Preventive and Cardiac Rehabilitation at Cedars-Sinai Medical Center, joins Heart Team to discuss current challenges in women’s cardiovascular disease research and clinical advancement. Gulati also provides guidance on improving female trial enrollment strat...

In the first episode from this new cardiovascular medicine series, hosts Dr. Jorge Plutzky and Dr. Michael Farkouh speak with University of Maryland's Dr. Matthew Weir about the growing involvement of renal care in modern heart disease patients.

The second episode of the 2-part Rare Disease Report shifts to a clinical perspective with the expertise of Dr. Pestana, a pediatric epileptologist at the Epilepsy Center, Cleveland Clinic Neurological Institute who treats patients with CDKL5 deficiency disorder (CDD).

In the first episode of a 2-part Rare Disease Report, Whitney Mitchell, mother and caregiver to her 6 year old daughter Havilah, shared her experience leading up to, and now living with, Havilah’s CDKL5 deficiency disorder (CDD) diagnosis.

This past week, the American Society of Retina Specialists (ASRS) held its 40th Annual Meeting in New York City to discuss landmark data and the newest advancements in retina care.  The HCPLive team was on-site at the Javits Center in Manhattan conducting interviews with expert retina specialists on topics including drugs for neovascular age-related macular degeneration and geographic atrophy, as...

On Monday, the US Food and Drug Administration (FDA) approved ruxolitinib cream 1.5% for the treatment of nonsegmental vitiligo in adults and pediatric patients 12 years and older, making it both the first FDA-approved therapy for repigmentation and the only topical formulation of a JAK inhibitor approved in the United States. The groundbreaking approval was supported by phase 3 data from the TRue...

Last week, the US Food and Drug Administration (FDA) approved the co-treatment of pegloticase (Krystexxa) injection plus methotrexate (MTX) for uncontrolled gout, a decision bolstered by data from phase 4 of the MIRROR study. In that study, 71% of patients who were treated with this combination therapy achieved a complete response over the course of 6 months. Comparatively, only 38.5% of patients...

Despite a bevy of biologics available for people struggling with Crohn’s disease and ulcerative colitis (UC), not all patients are able to respond to or tolerate a vast majority of approved therapies. Fortunately, new data presented at Digestive Disease Week (DDW) 2022 suggests that ustekinumab (STELARA) could function as an alternative option to bio-failure and bio-naïve patients living with thes...

If you’ve been keeping an eye on recent developments in ophthalmic care, then you’ll know that several new therapeutic agents that had been approved by the US Food and Drug Administration (FDA) in recent months, including ranibizumab delivered via Port Delivery System (PDS) and faricimab , the latter of which became the first-of-its-kind intravitreal bispecific biologic therapy for both age-relate...

Earlier this month, dupilumab became the first and only biologic medicine approved by the US Food and Drug Administration for the treatment of atopic dermatitis in patients of all ages, from infancy through adulthood. The approval of dupilumab as an add-on maintenance therapy for children 6 months to 5 years with moderate to severe atopic dermatitis was described as “a tremendous advancement” by M...

On June 13, the US Food and Drug Administration (FDA) approved oral baricitinib (Olumiant) tablets for the treatment of severe alopecia areata in adults, which marked the first approval of a systemic treatment for the disorder. The approval has excited patients and providers alike who struggled for decades to treat severe cases of this autoimmune disorder. For this episode of DocTalk , several key...

 On June 13, the US Food and Drug Administration (FDA) approved oral baricitinib (Olumiant) tablets for the treatment of severe alopecia areata in adults, which marked the first approval of a systemic treatment for the disorder. The approval has excited patients and providers alike who struggled for decades to treat severe cases of this autoimmune disorder. For this episode of DocTalk, several key...

After presenting at the SLEEP 2022 annual meeting, Dr. Aric Prather explains the findings of his previous research demonstrated lack of sleep (6 hours or less) was associated with a 4 times higher risk of becoming sick after exposure to rhinovirus in an interview with HCPLive . Currently, Prather and his team at UCSF are working with a large naive population for a study that began in March 2021. T...

In recognition of National Scleroderma Awareness Month, HCPLive spoke with several prominent dermatologists today who addressed some of the concerns and advancements related to the rare, multi-system disease. Scleroderma is often referred to as “morphea” by dermatologists, and the condition typically presents with the tightening and hardening of the skin. Depending on the region of the body, it ca...

Mikkael Sekeres, MD, is no stranger to rare disease. In his own words, there are rare diseases and then there are very rare diseases. Sickle cell is a rare condition with an incidence rate of just over 100 per 100,000 people. Sekeres focuses much of his treatment on patients with bone marrow disorders like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These conditions have an i...

Last week , the US Food and Drug Administration approved tapinarof cream, 1% (VTAMA) for the treatment of plaque psoriasis of all severities in adult patients, ushering in the first and only FDA-approved steroid-free topical medication in its class. Remarkably, it had been 25 years since a novel chemical entity had been introduced into psoriasis care from a brand-new mechanism of action, and from...